Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial

Fig. 3

Sixth-month graft biopsies. a Representative sections of livers stained with hematoxylin and eosin (H&E), including cases of nonrejection and rejection during MSC or rituximab treatment (×200 magnification). Severe portal vein endotheliitis and bile duct damage in liver biopsy specimens were observed with rejection (RAIS: 6–7). Mild portal inflammation and bile duct inflammation and damage were observed without rejection (RAIS: 1–3). RAIS=P(n1) + V(n2) + B(n3). b Representative IHC images of CD4, CD8, C4d, and CD20 staining, including cases of nonrejection and rejection during MSC or rituximab treatment (× 200 magnification). The positive staining of CD4 and CD8 reflects the inflammatory infiltration of T cells with rejection. The positive staining of C4d and CD20 suggests AMR. Abbreviations: MSC mesenchymal stem cell, RAIS rejection activity indexes, P(n1) scores for portal inflammation, V(n2) scores for venous endothelial inflammation, B(n3) scores for bile duct inflammation damage, AMR antibody-mediated rejection

Back to article page